Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823486 | 0.77 | MAOA (0.47) | MAOAMAOBSORT1 | |
| SCHEMBL9052322 | 0.75 | MAOA (0.39) | MAOAMAOBSORT1 | |
| SCHEMBL8706455 | 0.75 | MAOA (0.39) | MAOAMAOBSORT1 | |
| SCHEMBL1682384 | 0.73 | MAOA (0.38) | MAOAMAOBSORT1 | |
| SCHEMBL4244976 | 0.72 | AKR1B1 (0.39) | MAOAMAOBSORT1 | |
| SCHEMBL253210 | 0.71 | CYP2D6 (0.38) | MAOAMAOB | |
| SCHEMBL15284925 | 0.71 | MAOA (0.46) | MAOAMAOB | |
| SCHEMBL3074959 | 0.70 | MAOA (0.50) | MAOAMAOB | |
| SCHEMBL9559375 | 0.69 | SMN1; SMN2 (0.45) | SORT1 | |
| Propionic Acid SCHEMBL16830271 | 0.69 | SORT1 (0.36) | MAOAMAOBSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799913-B2 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1448537-A4 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20040259871-A1 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC | 2004-12-23 | — | — | US | disclosed |
| EP-1448537-A2 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045315-A2 | CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259871-A1 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | GAP43, GRIN2B, GRIN2A | MAOA 370/4885MAOB 109/4885SORT1 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.